Jennifer E. Golden
LightNews LightNews
banner
thegoldenlab.bsky.social
Jennifer E. Golden
@thegoldenlab.bsky.social
12 followers 14 following 2 posts
Synthetic medicinal chemist focused on heterocycle synthesis, molecular rearrangements, and infectious disease drug development. Professor, scientist, and mentor at the University of Wisconsin-Madison.
Posts Replies Media Videos
thegoldenlab.bsky.social
Celebrating Golden graduate student, Caroline Roach, who took 2nd place for her scientific talk on Chikungunya antivirals at the 62nd annual MIKIW conference! Keep an eye out for this manuscript - coming soon! Congrats, Caroline!
April 28, 2025 at 2:55 AM
thegoldenlab.bsky.social
Thanks @loriferrins.bsky.social for hosting my visit to NEU last week! It was a delight to share our group's chemistry and anti-infective drug discovery research efforts while getting a front row seat to the remarkable science going on at Northeastern University.
April 15, 2025 at 8:28 PM
Reposted by Jennifer E. Golden
dndi.org
The disclosure was made by @griffen-ed.bsky.social at the #ACSSpring2025 conference in San Diego. (2/10)
ACS talk 4181593 - Discovery of non-peptidomimetic oral combined MERS and SARS-CoV-2 anti-virals Presented by Ed Griffen Part of the session "Developing Countermeasures for Viruses of Pandemic Potential" Here we report the discovery of a family non-peptidomimetic spirolactams that target critical pathogenic coronaviridae including SARS-CoV-2 and MERS-CoV. As part of the ASAP AViDD centre(www.asapdiscovery.org) we expanded the work of the COVID Moonshot's drug discovery campaign targeting the SARS-CoV-2 main protease to deliver orally active compounds with promising in vivo profiles. Using a combination of active learning based medicinal chemistry, alchemical free energy calculations and structure-based design we were able to extend the coronavirus spectrum and optimise the ADMET properties of the series leading to the first public disclosure of the preclinical candidate.
March 25, 2025 at 7:33 PM